Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.